When treated with incretin-associated agents, the pancreatic and extra-pancreatic effects of these agents can be anticipated in patients with type 2 diabetes, leading to favorable blood glucose control without increasing body weights [25-27]. Here, GCG is linked to type 2 diabetes mellitus.